



Billing and Coding Guide for VYEPTI™ (eptinezumab-jjmr)

Lundbeck is committed to patient access and providing reimbursement information to support access to VYEPTI throughout the patient journey. Additional information about the billing and coding of VYEPTI can be obtained in the following ways:

- **VYEPTI CONNECT™** is an optional program that provides information and support to help with reimbursement issues. Once enrolled, you will be assigned a VYEPTI CONNECT Liaison who can be contacted at 833-4-VYEPTI, Monday through Friday, 8 AM - 8 PM EST.
- **Field Reimbursement Specialists (FRSs)** can assist with reimbursement questions over the phone or in person. Contact your Lundbeck representative to be connected to your FRS.

Indication

VYEPTI™ is indicated for the preventive treatment of migraine in adults.

Please see the Important Safety Information on back cover and accompanying full Prescribing Information including Patient Information.



Codes That May Help With Billing and Reimbursement

Below is a list of codes that may be useful for the billing and reimbursement of VYEPTI™ (eptinezumab-jjmr). It is important to note that the codes listed here are examples only and are not inclusive of all codes that may be applicable. The use of the following codes does not guarantee reimbursement.

Summary of Relevant Codes¹

ICD-10-CM	Description
G43	MIGRAINE
G43.0	MIGRAINE WITHOUT AURA
G43.00	MIGRAINE WITHOUT AURA, NOT INTRACTABLE
G43.001	MIGRAINE WITHOUT AURA, NOT INTRACTABLE, WITH STATUS MIGRAINOSUS
G43.011	MIGRAINE WITHOUT AURA, INTRACTABLE, WITH STATUS MIGRAINOSUS
G43.019	MIGRAINE WITHOUT AURA, INTRACTABLE, WITHOUT STATUS MIGRAINOSUS
G43.1	MIGRAINE WITH AURA
G43.10	MIGRAINE WITH AURA, NOT INTRACTABLE
G43.101	MIGRAINE WITH AURA, NOT INTRACTABLE, WITH STATUS MIGRAINOSUS
G43.109	MIGRAINE WITH AURA, NOT INTRACTABLE, WITHOUT STATUS MIGRAINOSUS
G43.11	MIGRAINE WITH AURA, INTRACTABLE
G43.111	MIGRAINE WITH AURA, INTRACTABLE, WITH STATUS MIGRAINOSUS
G43.119	MIGRAINE WITH AURA, INTRACTABLE, WITHOUT STATUS MIGRAINOSUS
G43.4	HEMIPLEGIC MIGRAINE
G43.40	HEMIPLEGIC MIGRAINE, NOT INTRACTABLE
G43.401	HEMIPLEGIC MIGRAINE, NOT INTRACTABLE, WITH STATUS MIGRAINOSUS
G43.409	HEMIPLEGIC MIGRAINE, NOT INTRACTABLE, WITHOUT STATUS MIGRAINOSUS
G43.41	HEMIPLEGIC MIGRAINE, INTRACTABLE
G43.411	HEMIPLEGIC MIGRAINE, INTRACTABLE, WITH STATUS MIGRAINOSUS
G43.419	HEMIPLEGIC MIGRAINE, INTRACTABLE, WITHOUT STATUS MIGRAINOSUS
G43.5	PERSISTENT MIGRAINE AURA WITHOUT CEREBRAL INFARCTION
G43.50	PERSISTENT MIGRAINE AURA WITHOUT CEREBRAL INFARCTION, NOT INTRACTABLE
G43.501	PERSISTENT MIGRAINE AURA WITHOUT CEREBRAL INFARCTION, NOT INTRACTABLE, WITH STATUS MIGRAINOSUS
G43.509	PERSISTENT MIGRAINE AURA WITHOUT CEREBRAL INFARCTION, NOT INTRACTABLE, WITHOUT STATUS MIGRAINOSUS
G43.51	PERSISTENT MIGRAINE AURA WITHOUT CEREBRAL INFARCTION, INTRACTABLE
G43.511	PERSISTENT MIGRAINE AURA WITHOUT CEREBRAL INFARCTION, INTRACTABLE, WITH STATUS MIGRAINOSUS
G43.519	PERSISTENT MIGRAINE AURA WITHOUT CEREBRAL INFARCTION, INTRACTABLE, WITHOUT STATUS MIGRAINOSUS
G43.6	PERSISTENT MIGRAINE AURA WITH CEREBRAL INFARCTION
G43.60	PERSISTENT MIGRAINE AURA WITH CEREBRAL INFARCTION, NOT INTRACTABLE

Important Safety Information

CONTRAINDICATIONS

- VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

Summary of Relevant Codes¹ (cont'd)

ICD-10-CM	Description
G43.7	CHRONIC MIGRAINE WITHOUT AURA
G43.70	CHRONIC MIGRAINE WITHOUT AURA, NOT INTRACTABLE
G43.701	CHRONIC MIGRAINE WITHOUT AURA, NOT INTRACTABLE, WITH STATUS MIGRAINOSUS
G43.709	CHRONIC MIGRAINE WITHOUT AURA, NOT INTRACTABLE, WITHOUT STATUS MIGRAINOSUS
G43.71	CHRONIC MIGRAINE WITHOUT AURA, INTRACTABLE
G43.711	CHRONIC MIGRAINE WITHOUT AURA, INTRACTABLE, WITH STATUS MIGRAINOSUS
G43.719	CHRONIC MIGRAINE WITHOUT AURA, INTRACTABLE, WITHOUT STATUS MIGRAINOSUS
G43.8	OTHER MIGRAINE
G43.80	OTHER MIGRAINE, NOT INTRACTABLE
G43.801	OTHER MIGRAINE, NOT INTRACTABLE, WITH STATUS MIGRAINOSUS
G43.809	OTHER MIGRAINE, NOT INTRACTABLE, WITHOUT STATUS MIGRAINOSUS
G43.81	OTHER MIGRAINE, INTRACTABLE
G43.811	OTHER MIGRAINE, INTRACTABLE, WITH STATUS MIGRAINOSUS
G43.819	OTHER MIGRAINE, INTRACTABLE, WITHOUT STATUS MIGRAINOSUS
G43.82	MENSTRUAL MIGRAINE, NOT INTRACTABLE
G43.821	MENSTRUAL MIGRAINE, NOT INTRACTABLE, WITH STATUS MIGRAINOSUS
G43.829	MENSTRUAL MIGRAINE, NOT INTRACTABLE, WITHOUT STATUS MIGRAINOSUS
G43.83	MENSTRUAL MIGRAINE, INTRACTABLE
G43.831	MENSTRUAL MIGRAINE, INTRACTABLE, WITH STATUS MIGRAINOSUS
G43.839	MENSTRUAL MIGRAINE, INTRACTABLE, WITHOUT STATUS MIGRAINOSUS
G43.9	MIGRAINE, UNSPECIFIED
G43.90	MIGRAINE, UNSPECIFIED, NOT INTRACTABLE
G43.901	MIGRAINE, UNSPECIFIED, NOT INTRACTABLE, WITH STATUS MIGRAINOSUS
G43.909	MIGRAINE, UNSPECIFIED, NOT INTRACTABLE, WITHOUT STATUS MIGRAINOSUS
G43.91	MIGRAINE, UNSPECIFIED, INTRACTABLE
G43.911	MIGRAINE, UNSPECIFIED, INTRACTABLE, WITH STATUS MIGRAINOSUS
G43.919	MIGRAINE, UNSPECIFIED, INTRACTABLE, WITHOUT STATUS MIGRAINOSUS
G43.A	CYCLICAL VOMITING
G43.A0	CYCLICAL VOMITING, NOT INTRACTABLE
G43.A1	CYCLICAL VOMITING, INTRACTABLE
G43.B	OPHTHALMOPLEGIC MIGRAINE
G43.B0	OPHTHALMOPLEGIC MIGRAINE, NOT INTRACTABLE
G43.B1	OPHTHALMOPLEGIC MIGRAINE, INTRACTABLE

ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification.

Lundbeck cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payer, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payers following the receipt of claims. For additional information, customers should consult with their payers for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.

Please see the Important Safety Information on back cover and accompanying full Prescribing Information including Patient Information.

Additional Codes That May Be Useful

Here are some miscellaneous codes that may be needed when submitting a claim for VYEPTI™ (eptinezumab-jjmr). Note that when these codes are used, health plans may require additional documentation. VYEPTI CONNECT Liaisons can provide you with any additional documentation. Note also that as payers may have individual coding preferences, Lundbeck recommends verifying the coding policies of health plans.

CPT® Code for VYEPTI Administration

CPT® codes consist of 5 characters. They describe medical procedures and services.² The following CPT code may be appropriate to report IV administration services.

Code ³	Description
96365	INTRAVENOUS INFUSION, FOR THERAPY, PROPHYLAXIS, OR DIAGNOSIS, INITIAL INFUSION, UP TO 1 HOUR

CPT=Current Procedural Terminology.

J-Codes (Level II HCPCS Codes)

J-codes are a subset of the HCPCS Level II code set mainly used to identify injectable drugs. J-codes typically include drugs that cannot be self-administered and are medically necessary for the treatment of an injury or illness. A J-code may cover the supply, injection, or infusion of a drug or biologic.⁴ The following J-codes may be appropriate for VYEPTI.

Code ^{5,6}	Description
J3490	UNCLASSIFIED DRUGS, ADMINISTERED BY INJECTION
J3590	UNCLASSIFIED BIOLOGICS

HCPCS=Healthcare Common Procedure Coding System.

C-Code (Level II HCPCS Code)

C-codes are HCPCS temporary pricing codes used for Medicare on claims for hospital outpatient department services and procedures.⁷

Code ⁸	Description	Site of Service
C9399	UNCLASSIFIED DRUGS OR BIOLOGICS	OUTPATIENT HOSPITAL

NDC for VYEPTI

An NDC is a unique, three-segment number used as a universal product identifier to report drug products.⁹ The NDC for VYEPTI is as follows.

Code ¹⁰	Description
67386-130-51	CARTON CONTAINING ONE 100 MG/ML SINGLE-DOSE VIAL

NDC=National Drug Code.

Important Safety Information (cont'd)

WARNINGS AND PRECAUTIONS

- Hypersensitivity reactions:** Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Sample Claim Form CMS 1500 (Physician's Office)

Below is a sample form CMS 1500 with tips on submitting claims for VYEPTI™ (eptinezumab-jjmr).

BOX 19: Additional Claim Information
Enter the number of units administered and not used, as well as any additional information that may be required (eg, miscellaneous HCPCS code)

BOX 21: Diagnosis or Nature of Illness or Injury
Record the appropriate ICD-10-CM diagnosis code from the patient's medical record

BOX 24A: National Drug Code
For physician-administered drugs such as VYEPTI, enter the NDC in the shaded area of Box 24A. When billing with a miscellaneous HCPCS code, the NDC should be included in Box 19

BOX 24D: Procedures, Services, or Supplies
Enter the appropriate HCPCS codes, CPT codes, and code modifiers for VYEPTI as specified by the payer

BOX 24E: Diagnosis Pointer
Record the diagnosis code number from Box 21 that applies to the procedure code indicated in Box 24D

BOX 24G: Service Units
When billing with a miscellaneous HCPCS code, a "1" must be entered

Lundbeck cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payer, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payers following the receipt of claims. For additional information, customers should consult with their payers for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.

Please see the Important Safety Information on back cover and accompanying full Prescribing Information including Patient Information.

● Support Throughout the Reimbursement Process

VYEPTI CONNECT™ is an optional program that provides information and support for reimbursement issues. Once enrolled, you will be assigned a VYEPTI CONNECT Liaison who can be contacted at 833-4-VYEPTI, Monday through Friday, 8 AM - 8 PM EST, to assist with reimbursement questions.

Field Reimbursement Specialists can assist with reimbursement questions over the phone or in person. Contact your Lundbeck representative to be connected to your FRS.

Indication

VYEPTI™ is indicated for the preventive treatment of migraine in adults.

Important Safety Information

CONTRAINDICATIONS

- VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

WARNINGS AND PRECAUTIONS

- **Hypersensitivity reactions:** Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

ADVERSE REACTIONS

- The most common adverse reactions ($\geq 2\%$ and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, see the accompanying full Prescribing Information including Patient Information.

References: **1.** ICD10Data website. <https://www.icd10data.com/ICD10CM/Codes/G00-G99/G40-G47/G43->. Accessed January 31, 2020. **2.** What is CPT®? AAPC website. <https://www.aapc.com/resources/medical-coding/cpt.aspx>. Accessed January 31, 2020. **3.** BioPortal website. <http://bioportal.bioontology.org/ontologies/CPT?p=classes&conceptid=96365>. Accessed January 31, 2020. **4.** HCPCS website. <https://hcpcs.org/jcodes>. Accessed January 31, 2020. **5.** AAPC website. <https://coder.aapc.com/hcpcs-codes/J3490>. Accessed January 31, 2020. **6.** HCPCS website. <https://hcpcs.org/J3590>. Accessed January 31, 2020. **7.** CMS website. <https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/downloads/MM5027.pdf>. Accessed January 31, 2020. **8.** HCPCS website. <https://hcpcs.org/c-codes/C9399/>. Accessed January 31, 2020. **9.** National Drug Code Directory. FDA website. <https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory>. Accessed January 31, 2020. **10.** VYEPTI [package insert]. Deerfield, IL. Lundbeck; 2020.